chr8-70131999-C-G
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM2BP4_Moderate
The NM_006540.4(NCOA2):c.3162G>C(p.Gln1054His) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a benign outcome for this variant. 13/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Consequence
NM_006540.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 0 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
NCOA2 | ENST00000452400.7 | c.3162G>C | p.Gln1054His | missense_variant | Exon 16 of 23 | 1 | NM_006540.4 | ENSP00000399968.2 | ||
NCOA2 | ENST00000518363.2 | c.537G>C | p.Gln179His | missense_variant | Exon 4 of 11 | 2 | ENSP00000429132.2 | |||
NCOA2 | ENST00000518287.6 | n.*119G>C | non_coding_transcript_exon_variant | Exon 15 of 21 | 5 | ENSP00000430148.2 | ||||
NCOA2 | ENST00000518287.6 | n.*119G>C | 3_prime_UTR_variant | Exon 15 of 21 | 5 | ENSP00000430148.2 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
not specified Uncertain:1
The c.3162G>C (p.Q1054H) alteration is located in exon 16 (coding exon 14) of the NCOA2 gene. This alteration results from a G to C substitution at nucleotide position 3162, causing the glutamine (Q) at amino acid position 1054 to be replaced by a histidine (H). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
No publications associated with this variant yet.